The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
Abstract
Despite the widespread adoption of reduced-intensity conditioning (RIC) for myeloma, there are few data comparing outcomes with RIC with myeloablative conditioning (MAC). We report the outcomes of patients undergoing allogeneic transplantations for myeloma and reported to the EBMT. A minimum data set was available on 320 RIC and 196 MAC allografts performed between 1998 and 2002. The RIC patients were older (51 vs 45 years) with more progressive disease (28% vs 21%) and more had received a prior transplant (76% vs 11%). In addition, there was a longer time to transplantation and an increased use of peripheral blood and T-cell depletion. For RIC and MAC, respectively, the nonrelapse mortality (NRM) at 2 years was 24% and 37% (P = .002); overall survival, 38.1% and 50.8% (not significant [ns]); and progression-free survival (PFS), 18.9% and 34.5% (P = .001). On multivariate analysis, RIC was associated with a reduction in NRM (HR, 0.5), but this was offset by an increase in relapse risk (HR, 2.0), and the conditioning intensity did not impact on overall survival or retain significance for PFS. These data suggest that there is a continuing need to investigate dose intensity in the conditioning for myeloma allografts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984 · cited 1×
“001 TCD* 127 (40) 82 (42) Alemtuzumab 65 (20) 13 (6) Unknown 10 (3) 19 (10) Year of transplantation 1998 to 1999 71 (22) 113 (58) .”
Cited by
Immunodeficiency and immunotherapy in multiple myeloma
Pratt, G., Goodyear, O., & Moss, P. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06705.x · Cited by 341
Guidelines for the diagnosis and management of multiple myeloma 2011
Bird, J. M., Owen, R. G., D’Sa, S., Snowden, J. A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08573.x · Cited by 306
Lim, Z., Brand, R., Martino, R., van Biezen, A., Finke, J., Bacigalupo, A., Beelen, D., Devergie, A., Alessandrino, E., Willemze, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8073 · Cited by 299
Self-citationManagement of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group
Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., et al. (2016) · Leukemia · doi:10.1038/leu.2015.356 · Cited by 258
Self-citation
Metadata
- Authors
- Crawley, C., Iacobelli, S., Björkstrand, B., Apperley, J. F., Niederwieser, D., Gahrton, G., & for the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-12-07
- Volume
- 109
- Issue
- 8
- Pages
- 3588-3594
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2024733207
- Cited by
- 181
- References
- 1
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. https://app.cochat.ai/papers/10.1182/blood-2006-07-036848
- The paper
- Crawley, C., Iacobelli, S., Björkstrand, B., Apperley, J. F., Niederwieser, D., Gahrton, G., & for the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). (2007). Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. https://doi.org/10.1182/blood-2006-07-036848
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.